Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

WuXi reaches into the biopharma hubs of Boston and San Francisco

WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.

PPD partners up with ERT for data collection

PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.

After CEO's death, Health Decisions brings in a Quintiles vet to lead its transition

Health Decisions, a week removed from the plane crash that claimed the life of its CEO, has recruited a CRO veteran from the University of North Carolina to step in as interim chief executive and oversee its transition.

BioClinica snags a Pfizer exec to take the helm

BioClinica, fresh from its latest merger, has named a Pfizer executive as its next CEO.

CRO Health Decisions carries on after CEO's death

North Carolina CRO Health Decisions is working its way back to normalcy after the death of its founder and CEO, processing a loss that "devastated" its staff, an executive said.

Investor cries foul over Covance's $6B sale to LabCorp

Covance got some bad advice when it agreed to a roughly $6 billion buyout from LabCorp, according to an investor lawsuit, which alleges that chief dealbroker Goldman Sachs had a conflict of interest all along.

DaVita grows its in-house CRO with a data-centric merger

Kidney dialysis magnate DaVita HealthCare Partners has merged its two research-minded subsidiaries to create an end-to-end CRO focused on renal trials.

Medidata burnishes its risk-based monitoring tech with latest buy

Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.

PPD's X-Chem pairs up with Alexion for drug discovery

X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.

INC Research lends its weight to trial site advocacy group

INC Research has deepened its partnership with the Society for Clinical Research Sites, supporting a training program and working to increase communication between trial sites and study investigators.